AstraZeneca advances cell therapy ambition with acquisition of EsoBiotec

17 March 2025

AstraZeneca (LSE: AZN) today revealed it has entered into a definitive agreement to acquire EsoBiotec, a Belgium-based biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity.

The deal marks the latest acquisition by AstraZeneca, which is Britain’s biggest listed company valued at £184 billion ($242 billion), as the pharmaceutical group continues to expand its global operations.

Its share price fell by 1% on Monday morning, when it also announced it has entered an exclusive license agreement with South Korea's Alteogen for ALT-B4, a novel hyaluronidase utilizing Hybrozyme platform technology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK